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LATED MORBIDITY AND EXCELLENT GVHD CONTROL
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Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2. Bio-
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Sirolimus (Rapamycin, Rap) is a novel immunosuppressant sim-
ilar to tacrolimus (Tac), however, Rap inhibits T cell function via
FKBP12/mTOR and may also inhibit dendritic cell function. Rap
is synergistic with Tac and has no overlapping toxicity, allowing
their use in combination. We have shown that Rap, Tac and
low-dose methotrexate (Mtx) is effective GVHD prophylaxis after
URD transplantation. Since Mtx is associated with transplant tox-
icity and since MRD GVHD rates are lower than URD rates, we
hypothesized that Rap and Tac, without Mtx, would provide ef-
fective GVHD prophylaxis after MRD PBSCT while minimizing
transplant-related morbidity and mortality (TRM). Methods: 30
subjects underwent PBSCT from 6/6 HLA-matched siblings(29)
or parents(1) after Cy/TBI conditioning. GVHD prophylaxis con-
sisted of Rap (serum level 3-12 ng/ml) and Tac (serum level 5-10
ng/ml). Filgrastim (5 g/kg) was administered from d12 until
engraftment if needed. Results: The median age of subjects was 42
years (range 19-54). Diagnoses were AML(8), MDS(7), CML(7),
NHL(6), ALL(1) and ATLL(1). The median times to neutrophil
engraftment (500/l) and platelet engraftment (20,000/l and
100,000/l) were 14 (range 11-17), 13 (range 10-47), and 19
(range 11-189) days respectively. All patients survived to discharge,
at a median of 18 days from day 0 (range 15-54). Gr. II GVHD
occurred in 3 patients (10%), involved the skin (3) and gut (1), and
resolved with corticosteroids. No patient developed Gr. III-IV
GVHD or idiopathic pneumonia syndrome. 4 patients developed
thrombotic microangiopathy, but recovered normal renal function
when Tac was held. VOD occurred in 3 patients. 1 patient had
CMV reactivation and none had invasive fungal infections. Oral
mucositis was mild and as a result, 47% of patients required no
TPN. The median number of days of TPN use was 6. 9/28
evaluable patients developed chronic GVHD (3 extensive, 6 lim-
ited). 6 patients with advanced malignancies relapsed. 22/30 pa-
tients remain alive in complete remission. Causes of death include
relapse(6), VOD(1) and late pulmonary toxicity(1). The median
follow-up is 253 days (range 34-466). Relapse-free and overall
survival at day 100 are 93 and 97%, and at 1 year are 70 and 66%.
Conclusions: Rap and Tac without Mtx is effective for GVHD
prophylaxis after MRD PBSCT. Due to Mtx omission, mucositis
was reduced, engraftment was prompt and TRM was reduced. This
combination is worthy of broader study in allogeneic transplantation.
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(PTS) WITH THALASSEMIA MAJOR: AN INFERIOR OUTCOME WHEN
ANTITHYMOCYTE GLOBLINS (ATG) IS ADDED TO THE CONDITIONING
REGIMEN
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Objectives: Allogeneic SCT is the only curative modality for pts
with Thalassemia Major. Busulfan (BU) and Cyclophosphamide (CY)
have traditionally been used as conditioning regimen with satisfactory
outcomes. ATG has been added by some investigators in heavily
transfused patients in an effort to reduce the risks of rejection. We
report here our SCT experience in Thalassemia pts showing an
inferior outcome in those who received ATG as part of the condi-
tioning regimen. Patients and Methods: From January 1998
through March 2001, 24 Thalassemia pts (11 class I, 11 class II, and
2 class III) underwent allogeneic SCT from HLA-matched related
donors at KFSHRC; median age was 4.5 years (range, 2-12.8 years),
conditioning was with BU 4 mg/kg/day p.o for 4 days, CY 50 mg/kg/
day i.v. for 4 days, and ATG 30 mg/kg/day i.v. for 4 days (group A).
Starting June 2001 through May 2003, ATG was removed from the
conditioning regimen; and 19 Thalassemia pts (12 class I, 5 class II,
and 2 class III) underwent matched related SCT with BU/CY only
(group B), median age was 4.5 years (range, 1.5-13.8 years). GVHD
prophylaxis was with Cyclosporin and MTX for both groups. Har-
vested marrow were not manipulated, median CD 34 dose was 8.8
106 (range, 2.3-17 106) and 8.6 106 (range, 4.9-14 106) per kg
of recipient body weight for groups A and B respectively. Engraftment
was assessed by VNTR or FISH on peripheral lymphocytes and/or
hemoglobin electrophoresis. Results: All pts had primary engraft-
ment; with a median time to ANC  0.5  109/L of 22 days (range,
14-29 days) and 18 days (range, 11-27 days) for the 2 groups respec-
tively, and a median time to self-sustaining platelet count of  20 
109/L of 18 days (range, 17-68 days) and 32.5 days (range, 16-68 days)
for the 2 groups respectively. Four pts in group A (16.6%) developed
severe acute GVHD (grade  3) of the skin, gut, and/or liver versus
only one patient in group B (5%). One patient in group A had chronic
GVHD versus 2 pts in group B. Secondary graft failure occurred in
ﬁve pts in group A and in none in group B. For group A, the 5 year
actuarial overall and event free survival was 86% and 65 % respec-
tively, and for group B, both the 2 year overall and event free survival
was 100%. Conclusions: Use of ATG in conditioning of Thalasse-
mia pts undergoing SCT is not beneﬁcial and appears to be associated
with a higher incidence of aGVHD and graft failure and with lower
survival.
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MARROW VERSUS PERIPHERAL BLOOD FOR GENO-IDENTICAL ALLO-
GENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOCYTIC LEU-
KAEMIA: INFLUENCE OF THE DOSE AND THE SOURCE OF STEM CELLS;
BETTER OUTCOME WITH RICH MARROW. ON BEHALF OF THE ACUTE LEUKAEMIA
WORKING PARTY (ALWP) OF THE EUROPEAN COOPERATIVE GROUP FOR BLOOD AND MARROW
TRANSPLANTATION (EBMT)
Gorin, N.C.1, Labopin, M.1, Rocha, V.2, Frassoni, F.3 1. Dept of
Hematology and Cell Therapy, Hopital Saint-Antoine, Paris, France,
Metropolitan; 2. Department of Hematology, Hopital Saint-Louis, Paris,
France, Metropolitan; 3. Department of Hematology, Ospedale San
Martino, Genova, Italy
Background: Several studies have compared bone marrow (BM)
and peripheral blood (PB) as stem cell sources in allografted patients,
but the cell doses infused have not been considered especially for
marrow. Material and methods: We studied retrospectively on the
ALWP/EBMT registry 881 adult patients with Acute Myelocytic
Leukaemia (AML), who received a non T depleted allogeneic BM
(n  515) or mobilised PB (n  366) standard transplant, in CR1,
from an HLA identical sibling, over a ﬁve year period from January
1994. Results: The BM cell dose ranged from 0.17 to 29  108/kg
with a median of 2.7 108/Kg. The PB cell dose ranged from 0.02 to
77  108/kg with a median of 9.3  108/kg.
Table. Major Differences in the Outcome of the 2 Groups
Group A Group B
Acute GVHD >3 Four One
Chronic GVHD One Two
Secondary graft failure Five None
Overall survival 86% 100%
Event free survival 65% 100%
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